Early detection and targeted screening reduces the risk of advanced cancer

Genetic testing for hereditary cancers can detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers, providing an in-depth cancer risk assessment for each patient.

  1. Hereditary Mutations for Oncogenetics

Hereditary cancer and genetic testing

Genetic testing provides early detection, and targeted screening reduces advanced cancer risk. This might save lives and it can help determine if your patient has an increased risk of certain types of cancer, such as breast, ovarian, colorectal, gastric, pancreatic, prostate, renal, skin, thyroid, uterine cancers or PGL/PCC/GIST adenomas.

Early detection of cancer can greatly improve the odds of successful treatment and survival.

The current state of science and research on hereditary cancer

Cancer is a disease of abnormal gene function. Scattered across our chromosomes are approximately 25,000 genes, which are functional units of DNA. The cell uses genes to make proteins and other substances that are necessary for life. In some genes, changes in the DNA called mutations have been linked to cancer.

Most cancers are thought to arise because of changes that occur during the lifetime of the affected person, but sometimes certain types of cancer seem to run in some families. In familial cases of cancer the cause might be an abnormal gene that is being passed along from generation to generation.

There are two types of mutations:

  • Germline (hereditary) gene mutation is present in every cell in the body and it can be passed on to the next generation.
  • Somatic (acquired) mutation is acquired during the lifetime of the patient, it is not present in all cells of the body and it cannot be passed on to the next generation.

In recent years, scientists have discovered a number of mutations that can contribute to a person’s risk of developing certain cancers, including breast, ovarian, colorectal and prostate cancer, as well as some other, less common, cancer types.

Why choose CENTOGENE?

Excellent analysis using the most advanced NGS technology

Includes detection of Copy Number Variants (CNVs)

Affordable prices and shortest turnaround times

Highest level of quality/accuracy

CAP and CLIA and ISO certification and accreditation

Find the right diagnostic service

The Sanger full-gene sequencing for an early cancer diagnostic.

Learn more

The comprehensive and sensitive panel with highly penetrant breast cancer genes.

Learn more

The specific and sensitive panel including 31 carefully selected genes based on their risk potential.

Learn more

Methodological summary of CENTOGENE’s hereditary cancer panels

  • Bidirectional NGS sequencing for all genes included in the panels (listed here below).
  • NGS panel analysis with complete 100% coverage for the target regions (technical accuracy of <98.1%).
  • For every panel gene, the complete coding sequence, exon/intron boundaries 10 bp into the intron, relevant promoter gene regions and all HGMD-described pathogenic variants are analyzed, with subsequent variant validation for any clinically relevant genetic variant detected.

Our medical and genetic experts can help determine which genetic testing is right to analyze the risk for hereditary cancer syndromes. After testing, result evaluation and specific recommendations for each individual case are necessary to decide on further steps for full patient care.

Downloads for Hereditary Mutations

  • One pager - Colon cancer with polyposis panel

  • Breast cancer testing - Patient information

    You can read all you need to know about breast cancer testing in our information brochure for patients. 


Portfolio for hereditary cancer testing

Single Gene Analysis

Latest scientific articles

CentoCard® – simplify your logistics

Sending patients´ samples as easy as mailing a postcard.

Order now

CentoPortal® – online ordering portal

Manage your genetic testing online supported by CentoCard®.

Read more

Get in touch with our Department of Medical Quality and Counseling

Our consultation service is available in several languages.

+49 (0) 381 - 80113 416

Mon. – Fri. 7 a.m.– 8 p.m. CET • Sat. – Sun. 9 a.m – 5 p.m. CET

For our US customers:

+1 (781) 270 1519

Mon. – Fri. 9 a.m. – 5.30 p.m. EST